Table 1.
Baseline clinical characteristics and biochemical measurements of the study groups
| NPWT group | Comparator group | p value | |
|---|---|---|---|
| Number of cases; n | 53 | 22 | NA |
| Sex; n M/F, % M | 45/8, 84.9% | 17/5, 77.3% | 0.42 |
| Age; yearsa | 65.4 ± 8.6 | 64.2 ± 6.8 | 0.54 |
| Duration of diabetes; yearsa | 14.3 ± 8.0 | 17.1 ± 7.4 | 0.17 |
| BMI; kg/m2 a | 29.8 ± 5.1 | 30.5 ± 4.9 | 0.60 |
| Insulin therapy; n Y/N, %Y | 50/3, 94.3% | 20/1, 95.2% | 0,87 |
| Daily dose of insulin; Ua | 55.3 ± 27.5 | 55.0 ± 25.9 | 0.97 |
| HbA1c; %a | 7.0 ± 1.3 | 7.4 ± 1.5 | 0.30 |
| HbA1c, mmol/mola | 53.5 ± 13.9 | 57.4 ± 16.8 | 0.30 |
| eGFR CKD EPI; ml/min/1,73 m2 a | 79.6 ± 21.7 | 74.5 ± 21.1 | 0.35 |
| eGFR < 60 ml/min/1,73 m2, % (n) | 20.8% (11) | 31.8% (7) | 0.31 |
| Total cholesterol; mmol/la | 3.3 ± 0.8 | 3.4 ± 0.9 | 0.75 |
| HDL; mmol/la | 0.9 ± 0.4 | 0.8 ± 0.1 | 0.90 |
| LDL; mmol/la | 2.0 ± 0.8 | 2.1 ± 0.7 | 0.45 |
| Triglycerides; mmol/la | 1.3 ± 0.6 | 1.5 ± 0.7 | 0.60 |
| Smoking; n current/former/never |
4/27/18 | 3/9/8 | 0.61 |
aData presented as mean ± SD